| Description | Differentially expressed in all three experimental groups: the control group and the CAD group, the control group and the T2DM group, the control group and the CAD and T2DM group. hsa-circRNA11783-2 was significantly lower in both the T2DM group and CAD group compared with the control group (in the second cohort). Hsa-circRNA11783-2 was downregulated in both the CAD and T2DM groups compared with the control group (in the third cohort), and the corresponding fold changes were 0.4 (p = 0.014) and 0.5 (p < 0.001) in the CAD and T2DM groups, respectively. Logistic regression analysis indicated that the crude OR of hsa-circRNA11783-2 was 0.740 [95% confidence interval (CI) = (0.630-0.869), p < 0.001] in the CAD group and 0.778 [(0.659-0.919), p = 0.003] in the T2DM group. After introducing the shared risk factors of CAD and T2DM (TC, TG, HDL, LDL, smoking and hypertension), the adjusted OR was 0.688 [(0.571-0.829), p < 0.001] in the CAD group and 0.723 [(0.591-0.883), p = 0.002] in the T2DM group. |